SCHEMBL14895754

SCHEMBL14895754

Nn1ncc2cccnc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
KDM4D Q6B0I6 1/20 0.44
PARP1 P09874 1/20 0.41
TSHR P16473 3/20 0.38
TP53 P04637 2/20 0.38
HSP90AA1 P07900 2/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 2/20 0.38
CYP3A4 P08684 2/20 0.38
MMP2 P08253 2/20 0.38
GMNN O75496 1/20 0.38
CYP2D6 P10635 1/20 0.38
MMP9 P14780 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
MMP8 P22894 1/20 0.38
CCR1 P32246 1/20 0.38
THPO P40225 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256383 0.75 KDM4E (0.55) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL21089903 0.75 KDM4E (0.59) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL3375873 0.75 KDM4E (0.55) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL7008753 0.75 KDM4E (0.55) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL17114770 0.75 KDM4E (0.55) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL23227964 0.75 KDM4E (0.55) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL4076644 0.72 PARP1 (0.54) KDM4EKDM4DPARP1CYP3A4FGFR1
SCHEMBL7701732 0.71 KDM4E (0.73) KDM4EKDM4DTSHRTP53HSP90AA1
SCHEMBL22607399 0.71 KDM4E (0.50) KDM4EKDM4DPARP1TSHRTP53
SCHEMBL983824 0.71 KDM4E (0.50) KDM4EKDM4DCYP3A4CYP2D6ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822464-B2 N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-02 US disclosed
US-20130137688-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-30 US disclosed
WO-2013063100-A1 ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2013-05-02 WO disclosed
WO-2013060029-A1 ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137688-A1 NOVEL COMPOUNDS GRM5, GRIN1, GRM1 KDM4E 1915/4885KDM4D 2953/4885PARP1 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.